Please assess the completion status of the following clinical trial:

Trial Title: Pharmacogenetic Study in Hepatocellular Carcinoma Patients.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Eligible patients should fulfill the following criteria:~  1. A diagnosed HCC patient.~ 2. Age ≥20 years.~ 3. Patients with adequate organ function.~ 4. HCC not eligible for curative measures (radiofrequency, microwave and surgery).~Exclusion Criteria:~* Patient will be excluded for any of the following:~  1. Patients refused to sign the written consent.~ 2. Age \> 75 years.~ 3. The presence of major portal vein thrombosis.~ 4. Extrahepatic metastases.~ 5. Hepatic encephalopathy.~ 6. Current infection.~ 7. Gastrointestinal bleeding within a month.~ 8. Uncontrolled ascites.~ 9. Serum bilirubin \> 3.0 mg/dl, serum albumin \< 2.8 g/dl, serum creatinine concentration \> 1.5 mg/dl, white blood cell counts \< 3,000/mm3 and platelet counts \< 30,000/mm3.~ 10. Patients with other types of malignancy, advanced organ failure, and advanced medical co-morbidity.~ 11. Pregnant females.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: None

Study Arms:
- HCC patients (Type: None): 116 hepatocellular carcinoma patients underwent TACE

Based on this trial design, predict the completion outcome and termination type (if applicable).